FOLH1 and neoplasm: Our pre-therapeutic dosimetry data demonstrate that [177Lu]Lu-rhPSMA-10.1 delivers an up to 8-fold greater radiation dose to the tumour compared with [177Lu]Lu-PSMA-I&T [6], which may be of clinical relevance when considering data obtained with [177Lu]Lu-PSMA-617 that suggest a better response to treatment is achieved when a greater radiation dose is delivered to the tumour [7, 8].